The Treatment Gap: Why Only 1 in 7 Americans with SUD Get Help
48.5 million people. ~15% treatment rate. Five structural reasons, and what would actually change them.
Body: [Five sections, each on one reason: (1) awareness/stigma, (2) navigation complexity, (3) insurance/affordability, (4) workforce shortage, (5) geographic deserts. Each section cites one stat and one actionable resource. Closes with what Rize and peers are trying to change.]
Sources Cited
- 01.A
Filed Under
The Treatment GapStigmaPeer-Reviewed ResearchFederal
Continue reading
More from this section
The Fourth Wave Breaks — and Tells Us Exactly Who Was Left Behind
A new peer-reviewed study in Addiction maps the 24.4% decline in U.S. overdose deaths in 2024 by race, ethnicity, and substance — revealing a historic drop driven by falling fentanyl deaths, persistent racial gaps, and a new crisis forming around stimulants and xylazine.
The Crisis, By the NumbersThe Numbers Are Good. The Explanation Is Contested.
CDC data projects 69,973 overdose deaths for 2025. Researchers are split between fentanyl supply disruption from China and harm reduction expansion as the primary driver. The answer determines what we protect and what we can afford to cut.
The Crisis, By the NumbersThe Decline Is Real. The Reason Should Unsettle Everyone.
The 13.9% drop in overdose deaths is real. But new research from Lancet identifies the drivers as market saturation and supply disruption — not the interventions we're currently funding or cutting.